Correlation of regional wall motion abnormalities detected by two-dimensional echocardiography with perfusion defect determined by technetium 99m sestamibi imaging in patients treated with reperfusion therapy during acute myocardial infarction.
Twenty patients (13 men and 7 women; mean age 61 +/- 12 years) with > 30 minutes chest pain and new ST-segment elevation who were treated with reperfusion therapy underwent technetium 99m sestamibi imaging and two-dimensional echocardiography simultaneously before and within 2 hours of each test after acute reperfusion therapy. Nine patients had anterior wall myocardial infarction. Fifteen patients were initially treated with intravenous thrombolytic agents, and five patients underwent urgent percutaneous transluminal coronary angioplasty. Both myocardial perfusion defect and wall motion score index (WMSI) improved after reperfusion therapy (perfusion defect from 28% to 15%, WMSI from 1.68 to 1.45, respectively; p < 0.005). The overall correlation between WMSI and perfusion defect as a measure of myocardium at risk was significant during the acute phase (r = 0.71) and at hospital dismissal (r = 0.71). Thus myocardial perfusion defect and wall motion abnormalities correlated fairly well in patients with acute myocardial infarction during the acute phase and at predismissal study.
Oh
J K
JK
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Gibbons
R J
RJ
Christian
T F
TF
Gersh
B J
BJ
Click
R L
RL
Sitthisook
S
S
Tajik
A J
AJ
Seward
J B
JB
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D003326:Coronary Circulation; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000628:therapy*; D010351:Patient Discharge; D012307:Risk Factors; D017256:Technetium Tc 99m Sestamibi; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D015899:Tomography, Emission-Computed, Single-Photon
D005343:Fibrinolytic Agents; D017256:Technetium Tc 99m Sestamibi; D010959:Tissue Plasminogen Activator